This analysis covers the four major emerging regions of the Middle East and Africa, Latin America, Eastern Europe, and Asia-Pacific. Within these regions, relatively wealthier markets with a proven marketplace for orphan medicines have been prioritized. The topic focus is on rare- disease policy, access, and pricing, as well as the stakeholder landscape for low-prevalence disorders and orphan drugs. For the purposes of this analysis, local definitions for rare disease were used where available, as well as conventional definitions of both “ultra-orphan” disorders and rare tumor types.

This Datamonitor Healthcare report contains a Strategy module.